Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients.
Milcent B, Josseaume N, Riller Q, Giglioli I, Rabia E, Deligne C, Latouche JB, Hamieh M, Couture A, Toutirais O, Lone YC, Jeger-Madiot R, Graff-Dubois S, Amorim S, Loiseau P, Toubert A, Brice P, Thieblemont C, Teillaud JL, Sibéril S. Milcent B, et al. Among authors: toutirais o. Cancer Immunol Immunother. 2019 Oct;68(10):1561-1572. doi: 10.1007/s00262-019-02389-7. Epub 2019 Sep 7. Cancer Immunol Immunother. 2019. PMID: 31494742 Free PMC article.
The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.
Gilardin L, Delignat S, Peyron I, Ing M, Lone YC, Gangadharan B, Michard B, Kherabi Y, Sharma M, Pashov A, Latouche JB, Hamieh M, Toutirais O, Loiseau P, Galicier L, Veyradier A, Kaveri S, Maillère B, Coppo P, Lacroix-Desmazes S. Gilardin L, et al. Among authors: toutirais o. Haematologica. 2017 Nov;102(11):1833-1841. doi: 10.3324/haematol.2015.136671. Epub 2017 Jul 27. Haematologica. 2017. PMID: 28751567 Free PMC article.
HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
Fauquembergue E, Toutirais O, Tougeron D, Drouet A, Le Gallo M, Desille M, Cabillic F, de La Pintière CT, Iero M, Rivoltini L, Baert-Desurmont S, Leprince J, Vaudry H, Sesboué R, Frébourg T, Latouche JB, Catros V. Fauquembergue E, et al. Among authors: toutirais o. J Immunother. 2010 May;33(4):402-13. doi: 10.1097/CJI.0b013e3181d366da. J Immunother. 2010. PMID: 20386466
Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H, Mönkkönen J, Boudjema K, Catros V, Bouet-Toussaint F. Cabillic F, et al. Among authors: toutirais o. Cancer Immunol Immunother. 2010 Nov;59(11):1611-9. doi: 10.1007/s00262-010-0887-0. Epub 2010 Jun 26. Cancer Immunol Immunother. 2010. PMID: 20582413 Free PMC article.
Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use.
Bouet-Toussaint F, Patard JJ, Gervais A, Genetet N, de la Pintière CT, Rioux-Leclercq N, Toutirais O, Thirouard AS, Ramée MP, Catros-Quemener V. Bouet-Toussaint F, et al. Among authors: toutirais o. Cancer Immunol Immunother. 2003 Nov;52(11):699-707. doi: 10.1007/s00262-003-0412-9. Epub 2003 Jul 15. Cancer Immunol Immunother. 2003. PMID: 12879292 Free PMC article. Clinical Trial.
Increased frequencies of circulating and tumor-resident Vδ1+ T cells in patients with diffuse large B-cell lymphoma.
Reboursiere E, Gac AC, Garnier A, Salaun V, Reman O, Pham AD, Cabrera Q, Khoy K, Vilque JP, Fruchart C, Chantepie S, Johnson-Ansah H, Macro M, Cheze S, Benabed K, Mear JB, Troussard X, Damaj G, Le Mauff B, Toutirais O. Reboursiere E, et al. Among authors: toutirais o. Leuk Lymphoma. 2018 Jan;59(1):187-195. doi: 10.1080/10428194.2017.1321751. Epub 2017 May 31. Leuk Lymphoma. 2018. PMID: 28562153
35 results